MMAF

Brentuximab vedotin has been shown to cause continuous positive responses in suppressing tumor regression in a majority of patients with relapsed or refractory CD30+ lymphomas. Currently, several auristatin analogous have been deployed as ADC payloads in clinical trials, including MMAF and a newly developed dolastatin 10 analogue PF-06380101.